Efficacy of levetiracetam in the treatment of drug-resistant Rett syndrome

Epilepsy Research

Volumn 88, Issue 2-3, 2010, Pages 112-117

  Specchio, Nicola ^a   Balestri, Martina ^a   Striano, Pasquale ^b   Cilio, Maria Roberta ^a   Nardello, Rosaria ^c   Patanè, Santina ^d   Margiotta, Maria Luisa ^d   D'Orsi, Giuseppe ^e   Striano, Salvatore ^b   Russo, Silvia ^f   Specchio, Luigi Maria ^g   Cusmai, Raffaella ^a   Fusco, Lucia ^a   Vigevano, Federico ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d ASL Lecce   (Italy)

^e Epilepsy Center   (Italy)

^f Medical Genetics   (Italy)

^g UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Drug resistance; EEG; Focal seizures; Levetiracetam; Myoclonic seizures; Rett syndrome

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; METHYL CPG BINDING PROTEIN 2; OXCARBAZEPINE; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; AGITATION; ARTICLE; ATONIC SEIZURE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; EPILEPSY; FEMALE; FOCAL EPILEPSY; FOLLOW UP; GENE MUTATION; HUMAN; IRRITABILITY; MONOTHERAPY; MYOCLONUS SEIZURE; ONSET AGE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RETT SYNDROME; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; TONIC CLONIC SEIZURE; TREATMENT DURATION;

ADOLESCENT; ANALYSIS OF VARIANCE; ANTICONVULSANTS; CHILD; DRUG ADMINISTRATION SCHEDULE; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; METHYL-CPG-BINDING PROTEIN 2; PATIENT SELECTION; PIRACETAM; PROSPECTIVE STUDIES; QUALITY OF LIFE; RETT SYNDROME; SEIZURES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 76049100714     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2009.10.005     Document Type: Article

References (28)

1. Berkovic S.F., Knowlton R.C., Leroy R.F., Schiemann J., Falter U., and Levetiracetam N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 69 (2007) 1751-1760
2. Birnstiel S., Wülfert E., and Beck S.G. Levetiracetam (ucb LO59) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission. Naunyn Schmiedebergs Arch. Pharmacol. 356 (1997) 611-618
3. Brodie M.J., Perucca E., Ryvlin P., Ben-Menachem E., Meencke H.J., and Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68 (2007) 402-408
4. Clemens B., Piros P., Bessenyei M., and Hollódy K. Lamotrigine decreases EEG synchronization in a use-dependent manner in patients with idiopathic generalized epilepsy. Clin. Neurophysiol. 118 (2007) 910-917
5. Glauser T.A., Ayala R., Elterman R.D., Mitchell W.G., Van Orman C.B., Gauer L.J., Lu Z., and N159 Study Group. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 66 (2006) 1654-1660
6. Glaze D.G. Neurophysiology of Rett syndrome. J. Child Neurol. 20 (2005) 740-746
7. Goyal M., O'Riordan M.A., and Wiznitzer M. Effect of topiramate on seizure and respiratory dysrithmia in Rett syndrome. J. Child Neurol. 19 (2004) 588-591
8. Haas R.H., Rice M.A., Trauner D.A., and Merritt T.A. Therapeutic effects of a ketogenic diet in Rett syndrome. Am. J. Med. Genet. Suppl. 1 (1986) 225-246
9. Hagberg B., Hanefeld F., Percy A., and Skjeldal O. An update on clinically applicable diagnostic criteria in Rett syndrome. Comments to Rett Syndrome Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology Society Meeting. Baden, Germany, 11 September 2001. Eur. J. Paediatr. Neurol. 6 (2002) 293-297
10. Hogart A., Nagarajan R.P., Patzel K.A., Yasui D.H., and Lasalle J.M. 15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders. Hum. Mol. Genet. 16 (2007) 691-703
11. Huppke P., Köhler K., Brockmann K., Stettner G.M., and Gärtner J. Treatment of epilepsy in Rett syndrome. Eur. J. Paediatr. Neurol. 11 (2007) 10-16
12. Kasteleijn-Nolst Trenité D.G., Marescaux C., Stodieck S., Edelbroek P.M., and Oosting J. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res. 25 (1996) 225-230
13. Liebhaber G.M., Riemann E., and Baumeister F.A. Ketogenic diet in Rett syndrome. J. Child Neurol. 18 (2003) 74-75
14. Niedermeyer E., Rett A., Renner H., Murphy M., and Naidu S. Rett syndrome and the electroencephalogram. Am. J. Med. Genet. 1 (1986) 195-199
15. Nieto-Barrera M., Nieto-Jiménez M., Díaz F., Campaña C., Sánchez M.L., Ruiz del Portal L., and Siljeström M.L. Clinical course of epileptic seizures in Rett's syndrome. Rev. Neurol. 28 (1999) 449-453
16. Noachtar S., Andermann E., Meyvisch P., Andermann F., Gough W.B., Schiemann-Delgado J., and N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 70 (2008) 607-616
17. Ogier M., and Katz D.M. Breathing dysfunction in Rett syndrome: understanding epigenetic regulation of the respiratory network. Respir. Physiol. Neurobiol. 164 (2008) 55-63
18. Palma E., Ragozzino D., Di Angelantonio S., Mascia A., Maiolino F., Manfredi M., Cantore G., Esposito V., Di Gennaro G., Quarato P., Miledi R., and Eusebi F. The antiepileptic drug levetiracetam stabilizes the human epileptic GABAA receptors upon repetitive activation. Epilepsia 48 (2007) 1842-1849
19. Reis J., Wentrup A., Hamer H.M., Mueller H.H., Knake S., Tergau F., Oertel W.H., and Rosenow F. Levetiracetam influences human motor cortex excitability mainly by modulation of ion channel function-a TMS study. Epilepsy Res. 62 (2004) 41-51
20. Samaco R.C., Hogart A., and LaSalle J.M. Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. Hum. Mol. Genet. 14 (2005) 483-492
21. Sannita W.G., Maggi L., Germini P.L., and Fioretto M. Quantitative EEG effects and plasma concentration of sodium valproate: acute and long-term administration to epileptic patients. Doc. Ophthalmol. 71 (1989) 413-419
22. Sannita W.G., Gervasio L., and Zagnoni P. Quantitative EEG effects and plasma concentration of sodium valproate: acute and long-term administration to epileptic patients. Neuropsychobiology 22 4 (1989) 231-235
23. Specchio N., Boero G., Michelacci R., Gambardella A., Giallonardo A.T., Fattouch J., Di Bonaventura C., de Palo A., Ladogana M., Lamberti P., Vigevano F., La Neve A., and Specchio L.M. Effects of levetiracetam on EEG abnormalities in juvenile myoclonic epilepsy. Epilepsia 49 (2008) 663-669
24. Steffenburg U., Hagberg G., and Hagberg B. Epilepsy in a representative series of Rett syndrome. Acta Paediatr. 90 (2001) 34-39
25. Stenbom Y., Tonnby B., and Hagberg B. Lamotrigine in Rett syndrome: treatment experience from a pilot study. Eur. Child Adolesc. Psychiatry 7 (1998) 49-52
26. Trauner D.A., and Haas R.H. Electroencephalographic abnormalities in Rett syndrome. Pediatr. Neurol. 3 (1987) 331-334
27. Uldall P., Hansen F.J., and Tonnby B. Lamotrigine in Rett syndrome. Neuropediatrics 24 (1993) 339-340
28. Zhang L., He J., Jugloff D.G., and Eubanks J.H. The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability. Hippocampus 18 (2008) 294-309